InflaRx (IFRX) Price/OCF Ratio: History & Chart

InflaRx N.V.(IFRX)

Biotechnology · Jena, TH

$1.64-0.04 (-2.68%)

Delayed quote: Oct 6, 2026, 11:09 AM EDT

About InflaRx N.V.

InflaRx N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and developing novel inhibitors leveraging C5a technology, primarily operating in Germany and the United States. The company's focus on C5a stems from its critical role as an inflammatory mediator implicated in the progression of various autoimmune and inflammatory diseases. Its primary product candidate, vilobelimab, is an innovative, first-in-class anti-C5a monoclonal antibody delivered intravenously. Vilobelimab has progressed through several clinical stages for multiple indications: It has successfully completed a Phase III clinical trial for hidradenitis suppurativa (HS), a rare, chronic, and debilitating systemic inflammatory skin condition. It is currently undergoing Phase II trials for anti-neutrophil cytoplasm antibody associated vasculitis (AAV), a rare and life-threatening autoimmune disorder, and for PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC). An exploratory Phase IIa study is also underway for pyoderma gangraenosum (PG), a chronic inflammatory skin disorder. Beyond its lead candidate, InflaRx is also advancing INF904, an oral, small molecule drug candidate targeting undisclosed chronic inflammatory and autoimmune diseases, and IFX002, which is in preclinical development for chronic inflammation and autoimmune conditions. Strategic collaborations include a co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. and a clinical trial collaboration and supply agreement with Merck & Co. Inc. Established in 2007, the company, initially known as Fireman B.V., officially became InflaRx N.V. in 2017. It maintains its headquarters in Jena, Germany, with operations extending to the United States.

Jena, TH

65 employees

www.inflarx.de

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Niels C. Riedemann

View full financials

NAME	MARKET CAP	PRICE/OCF RATIO	TTM	3Y	5Y
InflaRx N.V. (IFRX)	$240.82M	N/A	N/A	N/A	N/A
Galectin Therapeutics Inc. (GALT)vs ›	$240.71M	N/A	N/A	N/A	N/A
Akebia Therapeutics, Inc. (AKBA)vs ›	$242.56M	5.84	7.79	7.79	7.79
CAMP4 Therapeutics Corporation (CAMP)vs ›	$243.48M	N/A	N/A	N/A	N/A
Lifecore Biomedical, Inc. (LFCR)vs ›	$243.82M	N/A	252.82	252.82	155.13
Nautilus Biotechnolgy, Inc. (NAUT)vs ›	$249.31M	N/A	N/A	N/A	N/A
High Tide Inc. (HITI)vs ›	$238.13M	13.31	11.46	10.55	21.56
Greenwich LifeSciences, Inc. (GLSI)vs ›	$245.86M	N/A	N/A	N/A	N/A
BioAge Labs Inc. (BIOA)vs ›	$236.44M	N/A	N/A	N/A	N/A
Invivyd, Inc. (IVVD)vs ›	$246.29M	N/A	N/A	N/A	N/A

NAME

MARKET CAP

PRICE/OCF RATIO

TTM

InflaRx N.V. (IFRX)

$240.82M

N/A

Galectin Therapeutics Inc. (GALT)vs ›

$240.71M

N/A

Akebia Therapeutics, Inc. (AKBA)vs ›

$242.56M

5.84

7.79

CAMP4 Therapeutics Corporation (CAMP)vs ›

$243.48M

N/A

Lifecore Biomedical, Inc. (LFCR)vs ›

$243.82M

N/A

252.82

155.13

Nautilus Biotechnolgy, Inc. (NAUT)vs ›

$249.31M

N/A

High Tide Inc. (HITI)vs ›

$238.13M

13.31

11.46

10.55

21.56

Greenwich LifeSciences, Inc. (GLSI)vs ›

$245.86M

N/A

BioAge Labs Inc. (BIOA)vs ›

$236.44M

N/A

Invivyd, Inc. (IVVD)vs ›

$246.29M

N/A

Price/OCF Ratio Formula & Definition

P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.

Price/OCF Ratio: N/A

IFRX Price/OCF Ratio Metrics

IFRX Competitors' Price/OCF Ratio

Operating Cash Flow Valuation

Price/OCF Ratio Formula & Definition

Related Metrics